Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials
No abstract is available for this record.
Bibliographic context
- Journal
- Neuropharmacology
- Date
- 2025-11-01
- Source
- OpenAlex
- PubMed
- 41187880
Authors
Luisa ProchazkovaJosephine MarschallMichiel van ElkBen David RifkinNeil R SchonDonatella FiacchinoGeorge FejerMartin KuchařBernhard Hommel
Watch author
Topics and keywords
psilocybin Chronic PainPharmacologyMicrodosingCreativityClinical TrialRandomized Controlled Trial Randomized Controlled Trial PsilocybinPlaceboMedicineClinical trialPlacebo responseHallucinogenPharmacologyAnesthesiaRandomized controlled trialQuality (philosophy)PsychologyLongitudinal dataMEDLINECrossover studyClinical psychologyPsychedelics and Drug StudiesPain Management and Placebo EffectParanormal Experiences and Beliefs
Citation graph
0 referenced DOIs found in stored source metadata. 2 indexed papers cite this DOI.
Indexed papers citing this DOI
Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development2026-07-02Microdosing psilocybin and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials2025-11-01
Related papers
Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depressionTrials · 2024-07-02S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-18Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary Clinical Trials · 2022-11-01